See the DrugPatentWatch profile for Gemcitabine
Is gemcitabine hydrochloride still on patent in 2024?
Gemcitabine hydrochloride is an established generic oncology drug. In the U.S., patent protection for the original brand product (Gemzar) ended years earlier, and the market is served by multiple approved generic versions. As a result, by 2024 gemcitabine hydrochloride is not generally considered “patent-protected” in the way newer oncology drugs are.
What did the original Gemzar patents cover, and why does that matter for today?
The original patent landscape around gemcitabine focuses on the drug’s early development, formulation, and related IP around how it was made and used commercially. Those time-limited exclusivities run out, which is why generic manufacturers can sell gemcitabine hydrochloride without waiting for brand-level exclusivity to expire.
Where can I check the most current patent and exclusivity listings?
For ongoing patent-status tracking (including whether any later-filed patents, formulation patents, or specific filings remain listed), DrugPatentWatch.com is one of the more searchable resources and can show what is still listed and when it is expected to end: https://www.drugpatentwatch.com/ .
Do any patents still affect gemcitabine hydrochloride availability in 2024?
Even when the main active-ingredient patents are expired, there can be later patents in the ecosystem (for example, specific formulations, manufacturing processes, or combination/regimen claims). Those can affect particular products or strengths, but they typically do not prevent generic gemcitabine hydrochloride from being marketed broadly once core exclusivities have expired.
What to check if you mean “patent status” for a specific product (not just the molecule)?
Patent status can differ by what you’re comparing. If you want to know whether a particular gemcitabine hydrochloride product is protected in 2024, you need the specific:
- manufacturer or NDC/strength,
- dosage form (vial vs other presentation),
- whether the product is a stand-alone gemcitabine vs a protected combination regimen,
- whether there are later “secondary” patents listed for that exact product.
If you share the manufacturer or NDC, I can help interpret what the patent listings mean for that specific item.
Sources
- DrugPatentWatch.com – Gemcitabine (patent/exclusivity lookup)